How did Precigen's revenue and expenses trend in Q4 2024?

Precigen's revenue and expenses in Q4 2024 are not currently available. However, we can infer some trends based on the available data.

1. **Revenue Trend**: Precigen's revenue fell by 3.1% to $1.19 million in Q4 2024, compared to the same quarter in the previous year. This decline indicates a challenging period for the company in terms of generating income.
2. **Expense Trends**: The company reported an adjusted loss of 6 cents per share for Q4 2024, which is higher than the same quarter in the previous year when the company reported an EPS of -13 cents. This suggests that despite the revenue decline, the expenses have not been adequately managed, leading to a higher net loss.
3. **R&D and SG&A Expenses**: The specific values for R&D and SG&A expenses are not available. However, the fact that the company is actively pursuing regulatory approvals and clinical trials, as evidenced by the submission of the BLA for PRGN-2012, suggests that R&D expenses are likely to be high. The increased R&D expenses could be a result of the company's strategic focus on advancing its lead candidate to market.

In conclusion, Precigen faced a difficult quarter in Q4 2024, with revenue declining and expenses remaining high, leading to a higher net loss compared to the same quarter in the previous year. The company's focus on R&D, particularly in advancing PRGN-2012, is a key factor in the current expense trends.